Critical Parameters for the Development of Novel Therapies for Severe and Resistant Infections—A Case Study on CAL02, a Non-Traditional Broad-Spectrum Anti-Virulence Drug
Azeredo da Silveira, S.; Shorr, A.F. Critical Parameters for the Development of Novel Therapies for Severe and Resistant Infections—A Case Study on CAL02, a Non-Traditional Broad-Spectrum Anti-Virulence Drug. Antibiotics 2020, 9, 94. https://doi.org/10.3390/antibiotics9020094
Azeredo da Silveira S, Shorr AF. Critical Parameters for the Development of Novel Therapies for Severe and Resistant Infections—A Case Study on CAL02, a Non-Traditional Broad-Spectrum Anti-Virulence Drug. Antibiotics. 2020; 9(2):94. https://doi.org/10.3390/antibiotics9020094
Chicago/Turabian StyleAzeredo da Silveira, Samareh, and Andrew F. Shorr. 2020. "Critical Parameters for the Development of Novel Therapies for Severe and Resistant Infections—A Case Study on CAL02, a Non-Traditional Broad-Spectrum Anti-Virulence Drug" Antibiotics 9, no. 2: 94. https://doi.org/10.3390/antibiotics9020094